Methyldopa

Pharmacokinetics and prodrug principle

When taken orally, the drug exhibits fairly low bioavailability — no more than 50% of the initial dose enters the systemic circulation unchanged. However, the therapeutic value of methyldopa lies not in its peripheral action, but in its ability to freely cross the blood-brain barrier (BBB) and penetrate directly into the tissues of the central nervous system.

The drug's mechanism of action strictly follows the prodrug principle. Once in the brain, the parent molecule does not exert a direct effect, but undergoes a sequential two-step biochemical transformation:

1. In the first stage, the substance is converted into an intermediate metabolite — $\alpha$-methyldopamine.
2. In the second stage, final transformation into the active compound takes place — $\alpha$-methylnorepinephrine.

It is the resulting $\alpha$-methylnorepinephrine that acts as the target agent: it selectively stimulates $\alpha_2$-adrenergic receptors located on the membranes of neurons in the nucleus tractus solitarii.

Hemodynamic effects and duration of action

Stimulation of central $\alpha_2$-adrenergic receptors in the nucleus tractus solitarii triggers a cascade of hemodynamic changes that collectively provide a pronounced hypotensive effect. The process develops according to the following scenario:

• First and foremost, there is a significant decrease in vasomotor center tone.
• Following this, total peripheral vascular resistance (TPVR) predictably decreases as the blood vessels relax.
• An additional factor is the reduction in cardiac output indices.
• Summary of all changes: a reliable and stable decrease in blood pressure (BP).

It is important to consider the temporal characteristics of the drug. Because methyldopa takes time to cross the blood-brain barrier and undergo complex metabolic transformation within the CNS, the drug is unable to abort hypertensive crises. The onset of the therapeutic effect is delayed — registering only 3–5 hours after oral administration. At the same time, the achieved effect lasts for a long time, persisting throughout the day.

Wide range of side effects

The widespread use of methyldopa in routine practice is severely limited by a broad spectrum of side effects. Adverse reactions can affect various organ systems of the patient:

• Central nervous system: the most frequent complaints are pronounced sedation, lethargy, and persistent drowsiness.
• Autonomic manifestations: patients often experience dry mouth, gastrointestinal motility disorders (constipation), and orthostatic hypotension (a sharp drop in blood pressure when moving to a vertical position).
• Water-electrolyte balance: the drug actively promotes the retention of sodium ($Na^+$) ions and water in the body, which clinically manifests as the development of peripheral edema.
• Specific and severe reactions: with prolonged use, there is a risk of hepatotoxicity (severe liver dysfunction). Cases of drug-induced parkinsonism, severe hematological shifts (including leukopenia and hemolytic anemia), and marked sexual dysfunction have also been described.

Place in modern clinical practice

In modern pharmacological classification, methyldopa holds a place in the group of first-generation centrally acting antihypertensive agents. Its "neighbors" in this classification group include such well-known drugs as clonidine and guanfacine.

To date, the use of methyldopa in general cardiology practice is strictly limited. Physicians avoid prescribing it to a wide range of patients due to the high frequency of side effects, objective difficulties in selecting the optimal dosage, and the high risk of developing a dangerous withdrawal syndrome upon abrupt cessation of therapy.

Nevertheless, the drug has one completely unique and crucial clinical niche. Methyldopa is officially recognized as the drug of choice for the treatment of arterial hypertension in pregnant women. In this specific situation, proven safety for the fetus and reliability of blood pressure control completely outweigh the potential risks to the mother.

Briefly: answers to topical questions

Class and exam questions

What else to study on this topic

• Comparison of the pharmacodynamics of methyldopa, clonidine, and guanfacine.
• Mechanisms of development of hemolytic anemia and leukopenia when taking the drug.
• Pathogenesis of withdrawal syndrome of centrally acting antihypertensives.
• Causes of sodium ion and water retention during central sympatholytic therapy.
• Neurochemical basis of drug-induced parkinsonism development.

Other topics in the section "Cardiovascular Drugs"

Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.